PP405: Molecular Structure

Molecular Classification#

PP405 is a small molecule drug, not a peptide. It is included in this database because of its relevance to the broader landscape of hair growth therapeutics and its mechanism involving cellular signaling pathways.

Key Structural Information#

Relationship to Earlier MPC Inhibitors#

PP405 was developed from foundational research at UCLA that identified MPC inhibition as a mechanism to activate hair follicle stem cells. Earlier compounds in this class include:

• UK5099 (JXL001): The prototypical MPC inhibitor first described in the 1970s. An alpha-cyanocinnamate derivative that irreversibly inhibits MPC. Not suitable for clinical development as a topical therapy.
• JXL069: Another MPC inhibitor with CAS number 2260696-63-5. Pelage Pharmaceuticals has stated that PP405 is neither JXL069 nor JXL082.

PP405 appears to have been optimized for topical application with properties favoring skin penetration to the hair follicle while avoiding systemic absorption.

Pharmacokinetic Properties#

The most notable pharmacokinetic feature of PP405 is the absence of detectable systemic absorption:

• Topical penetration: PP405 penetrates the scalp to reach the hair follicle
• Systemic exposure: No PP405 was detected in blood plasma in either Phase 1 or Phase 2a trials
• Local action: The drug appears to act locally at the hair follicle and is either degraded locally or does not pass through the dermal barrier into systemic circulation
• Half-life: Not applicable for systemic pharmacokinetics given the absence of systemic absorption

Formulation#

PP405 is formulated as a 0.05% topical gel for once-daily scalp application. This concentration was selected based on preclinical optimization and Phase 1 dose-finding studies.

Molecular Context#

PP405 belongs to the Skin category of research peptides. The molecular properties of PP405 determine its pharmacological behavior, including receptor binding, distribution, metabolism, and elimination. Understanding these properties is fundamental to interpreting clinical data and designing research protocols.

Structural Overview#

PP405 is characterized as: PP405 is a proprietary small molecule inhibitor of the mitochondrial pyruvate carrier (MPC). Its exact chemical structure has not been publicly disclosed by Pelage Pharmaceuticals. It is distinct from earlier MPC inhibitors such as UK5099 (JXL001) and JXL069, though it shares the same pharmacological target..

Amino Acid Sequence Details#

The amino acid sequence of PP405 is: Not applicable (small molecule, not a peptide). This sequence determines the peptide's three-dimensional structure, receptor binding properties, and biological activity.

Pharmacokinetic Profile#

Half-Life: Not established (no systemic absorption detected)

The half-life of a peptide influences dosing frequency, duration of effect, and the clinical utility of the compound. Researchers should consider the half-life when designing experimental protocols.

Related Reading#

• PP405 overview and research guide
• Peptides similar to PP405
• PP405 research evidence